British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca PLC's India arm announced that it received additional indication approval from the Central Drugs Standard Control Organization (CDSCO) for the drug Durvalumab to treat biliary tract cancer (BTC) in India. BTC is a group of rare and aggressive gastrointestinal cancers that form in the...